Chinese local governments compete for startup biotechs

5 April 2018

Many high-profile startsups prefer crashing in crowded mega Chinese cities. For example, Zai Lab is located in Shanghai, and BeiGene chose to stay in Beijing, comments The Pharma Letter’s China correspondent Wang Fangqing.

Big cities have benefits like good infrastructure and rich talent pool, but the living cost and the cost of keeping talent is running so high that some entrepreneurs are looking for other places.

The good news is, as China is determined to improve value and quality across industries under the initiative “Made in China 2025,” many local governments, such as those in Hangzhou, Suzhou and Wuhan are competing hard for high-tech companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK